Review Article

Future Journal of Pharmaceuticals and Health Sciences

Published by Pharma Springs Publication Journal Home Page: https://pharmasprings.com/fjphs

A Review on Krabbe Disease

Palakurthi Yanadaiah*[1], Kotloni Sreekanth[2], Challa Likhitha[2], Chandana Chinthimi[2]

[1]Department of Pharmacy Practice, Sun Institute of Pharmaceutical Education and Research, Kakupalli (V), Nellore Rural (M), SPSR Nellore (Dist) - 524346, Andhra Pradesh, India
[2]Sun Institute of Pharmaceutical Education and Research, Kakupalli (V), Nellore Rural (M), SPSR Nellore (Dist) - 524346, Andhra Pradesh, India

Article History:

Received on: 20 Dec 2022
Revised on: 08 Jan 2023
Accepted on: 10 Jan 2023

Keywords:

Blood and Blood Products Cell Leukodystrophy, Krabbe Disorder, Lysosomal Collection Disorder

Abstract

Krabbe disorder was autophagosome collection disorder leading to gradual as well as eloquent neurodegenerative. Immature, childish, and individual types of Krabbe disorder have already been defined as ignorant, one of the most typical. Kids, including an infant, usually appear regularly from newborns and proceed to overlook the development stages within six months of aging and death within 2-3 years of life. Krabbe's disorder was the epistemology of dysfunction with acid hydrolase galactosyl ceramidase. Therapeutic approaches, including enzyme replacement, surface reduction, enzymatic activity chaperones, and genetic engineering, have already shown promise in LSDs. The success in recent years of combinational treatment strategies in minor mammal models like Krabbe disorder and the detection of early identification pathogenic methodologies focus on providing optimism again for developing more effective therapeutic interventions for this severe disease. The above study provided a quick background like Krabbe disorder & transformation like single and combined effect treatment interventions and described novel infective methods and how they may affect the event of further practical therapeutic approaches.

*Corresponding Author

Name: Palakurthi Yanadaiah
Phone: +91 9963109893
Email: yanathulasi@gmail.com

eISSN: 2583-116X pISSN:

DOI: https://doi.org/10.26452/fjphs.v3i1.352

Production and Hosted by

Pharmasprings.com

INTRODUCTION

Krabbe syndrome is a disorder of genetic abnormality of the central nervous this sometimes leads to death. Without such a myelin shield, Krabbe disease cells in the periphery will deteriorate, and the body's central nervous system won't function reliably. Approximately 85 to 90 % of Krabbe disorder cases proceed in infancy, but this can also establish early in adulthood. Nowadays no treatments for Krabbe disorder, and also most children with this disorder can cause death before age 2 [1].

Krabbe disorder (globoid cell leukodystrophy) is a degenerative brain situation. Myelin is the protective coating all over the nerve cells that helps ensure nerve signals' quick transformation. Krabbe disorder by impaired cells in the brain known as globoid cells, which are large cells that usually get more than one nucleus [2]. It becomes worse over time and commonly leads to death. Typically affecting infants below the age of 1, it can also affect older children and adults.

Krabbe Disorder Called by Some Names

1. Galactocerebrosidaselack age
2. Galactocerebroside beta-galactosidase deficiency
3. Galactosylceramide lipidosis

4. Globoid cell leukoencephalopathy
5. Krabbe's disorder
6. Leukodystrophy, Globoid cell
7. Sphingolipidosis, Krabbe's type

Definition

Krabbe disease is an inherited underlying genetic disease where in large doses, lipoproteins (fatty compounds including essential oils and waxes) start accumulating in assorted cells and tissues within the body and damage the brain cells [3].

Krabbe disorder occurs by the deficits of Galactocerebrosidase, a vital enzyme for myelin metabolism. The disease usually affects babies and children, beginning before six months, but it could arise in adolescence or adulthood [4].

Krabbe disease is a degenerative brain lysosomal storage disease caused by genetic variations. Krabbe disorder generally impacts newborns but has also been noted in older children and adults [Figure 1].

Age Less than 12 Months on Set Disorder

1. Excessive weeping completely excessive irritability,
2. Feeding struggles, gastroesophageal reflux disease,
3. Spasticity of lower limbs and tickling, with transverse hypotonia,
4. Loss of managed to acquire life events (smiling, cooing, and head control),
5. Staring episodes and
6. Peripheral neuropathy [1, 5].

Age Greater than 12 Months Later Onset

1. Slow development of motor managed to acquire life events or loss of life events, slurred speech,
2. Spasticity of extremities with truncal hypotonia,
3. Vision loss, esotropia,
4. Seizures,
5. Peripheral neuropathy,
6. Trouble eating,
7. Possible Seizures,
8. Loss of mental and muscle function,
9. Lose the ability to see and hear,
10. Can't walk, talk, or eat,
11. Slow reaction time,
12. Fever,
13. Crying for no reason and
14. Difficulty of sleep [6].

Causes

Krabbedisorder seems to result from chromosomal anomaly alterations within DNA genetic code, and it compose the specific mutation.

The genotype is just that, Krabbe disorder that did also find chromosome fourteen type. Infants necessary possess defective genes both from family developed the disease. This mutated genetics leads to a lack of a supply of essential enzymes in their bodies. However, adult-onset situations get such have distinct genetic mutations. Krabbe disorder patients will also have psychosine stages that are 100 times more excellent, while those who don't have always had the disorder [7, 8] [Figure 2].

Pathophysiology

It is feasible that certain psychosines produced deacylation galactosylceramide even though the supposition is now. Psychosine would not haven't a biological role in cell function anatomy with metachromatic leukodystrophy; enzyme activity deficiency ends in incapability cumulates galactosyl sulfatide, a glycolipid also galactosylceramide, the enlarged myelin [9]. That building the galactosyl sulfatide oligodendrocytes affects its medical metachromatic leukodystrophy, a disorder that progresses through injection of galactosylceramide in the brain. The cytotoxicity of psychosine has been very well evidenced [Figure 3]. They are injected into rat brains, and psychosine results in complicated hemorrhagic infarction, necrosis &myelin degradation. Psychosines have the causes of oligodendrocytes and Schwann cells in Vitro study [10]. Where psychosine-mediated death with myelin-forming cells causes through apoptosis, necrosis is still not evident. Oligodendrocytes occur apoptosis by twitcher mice found with TUNEL staining. Which secreted microglia and macrophages, where they actively followed the thepsychosine-mediated myelin degradation [11].

Oligodendrocyte apoptosis increases evidence mode by oligodendrocyte die to occur the psychosis by apoptosis. DNA fragmentation, and aspecific



Figure 1: Genetic Mutation



Figure 2: Chromosomal Pairing



Figure 3: Pathophysiology of Krabbe Disease

apoptosis, we observed by the MOCH-1 cells & culture fibroblasts that they might incubate by psychosine. Interestingly, that glial derives cells that are not needed. Apoptosis was marked higher than fibroblast, by recommended susceptibility by oligodendrocyte that apoptosis. No apoptotic cells observe to be controlled by apoptosis cells incubated with psychosine. In addition, laddering DNA extracted for the psychosine treatment cell detected further signals of apoptotic cell death [12].

Epidemiology

The German leukodystrophy connections system LEUKONET was financially backed between 2003 & 2011, indeed by criteria for acquiring every patient's details, and continues till 2017 [13].

Clinical leukocyte deformities assessed the clinical grounds of enzyme defusion. Leukodystrophic modifications of MRI. In some cases, the specific diagnosis has acknowledged the atom gene evaluation with both *GALC* genes. The patient populations included in the study have been diagnosed presymptomatically, e.g., based on genetic diagnostic by the case-impacted siblings. The research aims to characterize the disease's history and the following treatment. Medical documents & parents' documentary evidence of the child's disorders transforma-

tion complemented the survey questing data [14].

Identified different forms of the disorders as given information (see also Figure 1). The standardized assessment by gross motor function, the GMFC-MLD established.

Krabbe disorder according to age at onset. One MRI is done in a clinical context using standardized analysis. As a minimum, a T2-weight image was required [15]. In some cases, when the patient and the family are known, the author, through earlier patient care& contact, couldn't be developed without written informed consent.

Diagnostic

The newborn baby screening test for Krabbe disorder involves evaluating dry blood cells was GALC enzymatic reactions & small auto evaluation from the evidence of GALC enzyme mutations. A high concentration of psychosine in dry blood spots may identify as a marker for Krabbe disorder [16].

Tests that included:

1. Blood test to measure galactosylceramidase in WBC
2. CSF total protein – examination of (CSF)
3. Gene test for GALC
4. MRI of head
5. Nerve conduction velocity

Treatment

Children and infants with the disorder benefit from supportive therapy, and the following shows the advancement of the disease [17]**.** The umbilical cord blood transplant enlarges many children's life. Replacement is unsuitable for children, but the doctor discusses the option with the parents [15, 18]. Hematopoieticscell is not mature cells that can convert to all blood cells, including WBC, RBC, and platelets.

HSCT, hematopoietic cells by the healthy donor transplant with infants suffering from Krabbe disorder. HSCT helps the infant's body complete the brain through healthy cells and GALC enzyme activities. However, HSCT work when given before the onset of signs and symptom [2].

Research has been working on looking for the best therapeutics for Krabbe disorder. Presently there is no cure for Krabbe disorder& which gets worse over time; they may be different types management of supportive care, which may include:

1. Muscle relaxant for spasms.
2. Anticonvulsant medication to cure seizures.
3. Physical therapy by increasing mobility.
4. Occupational therapy for aged children and adults.
5. Tube feeding with proper nutrition of swallowing was affected.

CONCLUSION

Krabbe disorder was autophagosome collection disorder leading to gradual as well as eloquent neurodegenerative. Therapeutic approaches, including enzyme replacement, surface reduction, enzymatic activity chaperones, and genetic engineering, have already shown promise in LSDs. The success in recent years of combinational treatment strategies in minor mammal models like Krabbe disorder and the detection of early identification pathogenic methodologies focus on providing optimism again for developing more effective therapeutic interventions for this severe disease. The above study provided a quick background like Krabbe disorder & transformation like single and combined effect treatment interventions and described novel infective methods and how they may affect the event of further practical therapeutic approaches.

ACKNOWLEDGEMENT

The authors are thankful to the Management & Principal of Sun Institute of Pharmaceutical Education and Research, Kakupalli (V), Nellore Rural (M), SPSR Nellore (Dist) - 524346, Andhra Pradesh, India.

Funding Support

The authors declare that they have no funding support for this study.

Conflict of Interest

The authors declare that this study has no conflict of interest.

REFERENCES

[1] D A Wenger, M A Rafi, P Luzi, J Datto, and E Costantino-Ceccarini. Krabbe disease: genetic aspects and progress toward therapy. *Molecular genetics and metabolism*, 70(1):1–9, 2000.

[2] M S Tullu, M N Muranjan, P P Kondurkar, and B A Bharucha. Krabbe disease-Clinical profile. *Indian pediatrics*, 37(9):939–946, 2000.

[3] W Krivit, E G Shapiro, C Peters, J E Wagner, G Cornu, J Kurtzberg, and L A Lockman. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. *New England Journal of Medicine*, 338(16):1119–1127, 1998.

[4] W A Stewart, K E Gordon, P R Camfield, E P Wood, and J M Dooley. Irritability in krabbe's disease: dramatic response to low-dose morphine. *Pediatric neurology*, 25(4):344–345, 2001.

[5] W A Stewart, K E Gordon, P R Camfield, E P Wood, and J M Dooley. Irritability in krabbe's disease: dramatic response to low-dose morphine. *Pediatric neurology*, 25(4):344–345, 2001.

[6] M Turazzini, A Beltramello, R Bassi, R Del Colle, and M Silvestri. Adult onset Krabbe's leukodystrophy: a report of 2 cases. *Acta neurologica scandinavica*, 96(6):413–415, 1997.

[7] M Zeigler, J Zlotogora, R Regev, A Dagan, S Gatt, and G Bach. Prenatal diagnosis of Krabbe disease using a fluorescent derivative of galactosylceramide. *Clinica chimica acta*, 142(3):313–318, 1984.

[8] N P S Bajaj, A Waldman, R Orrell, N W Wood, and K P Bhatia. Familial adult onset of Krabbe's disease resembling hereditary spastic paraplegia with normal neuroimaging. *Neurosurgery & Psychiatry*, 72(5):635–638, 2002.

[9] R De Gasperi, M G Sosa, E L Sartorato, S Battistini, H Macfarlane, J F Gusella, and E H Kolodny. Molecular heterogeneity of late-onset forms of globoid-cell leukodystrophy. *American journal of human genetics*, 59(6):1233–1242, 1996.

[10] R Oehlmann, J Zlotogora, D A Wenger, and R G Knowlton. Localization of the Krabbe disease gene (GALC) on chromosome 14 by multipoint linkage analysis. *American journal of human genetics*, 53(6):1250–1255, 1993.

[11] I W Nicole, M H Vivi, S V K Marjo, et al. Leukodystrophies. *Neurology Clinical Practice*, 6(6):506–514, 2006.

[12] L A Cannizzaro, Y Q Chen, M A Rafi, and D A Wenger. Regional mapping of the human galactocerebrosidase gene (GALC) to 14q31 by in situ hybridization. *Cytogenetic and Genome Research*, 66(4):244–245, 1994.

[13] H Allewelt, M Taskindoust, J Troy, K Page, S Wood, S Parikh, and J Kurtzberg. Long-term functional outcomes after hematopoietic stem cell transplant for early infantile Krabbe disease. *Biology of Blood and Marrow Transplantation*, 24(11):2233–2238, 2018.

[14] J Cheung, A Rancourt, S Di Poce, A Levine, J Hoang, F Ismail, and C P Phadke. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. *Physiotherapy Canada*, 67(2):157–166, 2015.

[15] A Ghai, N Garg, S Hooda, and T Gupta. Spasticity-Pathogenesis, prevention and treatment strategies. *Saudi journal of anaesthesia*, 7(4):453–460, 2013.

[16] A G Rabchevsky and P H Kitzman. Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. *Neurotherapeutics*, 8(2):274–282, 2011.

[17] B Sharma, R B Sannegowda, K Nagpal, and R Jain. Wrist clonus mimicking as action-induced tremors: an important clinical lesson. *BMJ Case Reports*, page bcr2012006804, 2012.

[18] J Fletcher, P Williamson, and R Taylor. Krabbe disease in the Australian working Kelpie. *Orbit: University of Sydney Undergraduate Research Journal*, 1(1), 2009.

Cite this article: Palakurthi Yanadaiah, Kotloni Sreekanth, Challa Likhitha, Chandana Chinthimi. **A Review on Krabbe Disease**. Future J. Pharm. Health. Sci. 2023; 3(1): 98-103.